BCM
ACAD icon

BlueCrest Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

BlueCrest Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-46,764
Closed -$1.76M – 800
2017
Q3 		$1.76M Buy
+46,764
New +$1.52M 0.07% 274
2017
Q2 		– Sell
-9,424
Closed -$324K – 885
2017
Q1 		$324K Buy
+9,424
New +$333K 0.02% 508

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlueCrest Capital Management's ACAD Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 46,764 shares — an estimated $1.76M sold.

BlueCrest Capital Management first reported a position in ACAD in Q1 2017 and held it in 2 quarters. The position peaked at $1.76M in Q3 2017. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 46,764 Acadia Pharmaceuticals shares in Q4 2017, an estimated $1.76M.
  • BlueCrest Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Acadia Pharmaceuticals position peaked at $1.76M in Q3 2017.
  • 210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.